Talus Bio
Facts
Is this your organization? Claim it
Recent coverage
Front-page news, podcasts and videos about Talus Bio
Pack Ventures launches Seattle syndicate to back UW-linked startups, pledges 10% of future profits to University of Washington
Pack Ventures, a new early-stage Seattle VC, will invest $100K–$200K checks in startups tied to the University of Washington and has already backed five companies including Jeeva Wireless, Talus.bio and Monod Bio; the firm will return 10% of individual future profits to UW. The syndicate includes more than 35 founding investors from the Seattle VC and entrepreneur community and will target AI, robotics, computational biology, enterprise software and other high-growth areas.
Pack Ventures launches 506(c) pre-seed fund to back University of Washington founders, pledges 10% of returns to UW
Pack Ventures (Pack VC), a pre-seed and seed 506(c) fund, launched to invest in University of Washington-affiliated founders and broaden accredited investor access; leaders pledge 10% of personal fund returns to UW and will host an online introduction for accredited investors on Feb. 17.
By Talus Bio
See all 6Talus Bio names Chris Joyce, MBA as VP of Business Development to drive pharma deals and advance TF therapeutics
Talus Bio hired Chris Joyce, MBA as VP of Business Development to accelerate pharma partnerships and advance its transcription factor therapeutics, including two programs targeting TBXT for non-small cell lung cancer and NONO-related androgen receptor splicing in castration-resistant prostate cancer.
Talus Bio launches 'Drugging the Undruggable' blog series to advocate open-source science and structure-free drug discovery
Talus Bio launched a new blog series, Drugging the Undruggable, to promote open-source computational science and explain their structure-free AI approach to targeting intrinsically disordered proteins.
Talus Bio names Gaelle Mercenne, PhD as Head of Biology to advance AI-driven transcription factor drugs
Talus Bio hires Dr. Gaelle Mercenne as Head of Biology to lead preclinical development and AI-driven lead optimization for its transcription factor therapeutics, using the MARMOT platform and funds from an $11.2M seed extension to expand its discovery team.
